Communications Biology (May 2023)

Blocking muscle wasting via deletion of the muscle-specific E3 ligase MuRF1 impedes pancreatic tumor growth

  • Daria Neyroud,
  • Orlando Laitano,
  • Aneesha Dasgupta,
  • Christopher Lopez,
  • Rebecca E. Schmitt,
  • Jessica Z. Schneider,
  • David W. Hammers,
  • H. Lee Sweeney,
  • Glenn A. Walter,
  • Jason Doles,
  • Sarah M. Judge,
  • Andrew R. Judge

DOI
https://doi.org/10.1038/s42003-023-04902-2
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Cancer-induced muscle wasting reduces quality of life, complicates or precludes cancer treatments, and predicts early mortality. Herein, we investigate the requirement of the muscle-specific E3 ubiquitin ligase, MuRF1, for muscle wasting induced by pancreatic cancer. Murine pancreatic cancer (KPC) cells, or saline, were injected into the pancreas of WT and MuRF1-/- mice, and tissues analyzed throughout tumor progression. KPC tumors induces progressive wasting of skeletal muscle and systemic metabolic reprogramming in WT mice, but not MuRF1-/- mice. KPC tumors from MuRF1-/- mice also grow slower, and show an accumulation of metabolites normally depleted by rapidly growing tumors. Mechanistically, MuRF1 is necessary for the KPC-induced increases in cytoskeletal and muscle contractile protein ubiquitination, and the depression of proteins that support protein synthesis. Together, these data demonstrate that MuRF1 is required for KPC-induced skeletal muscle wasting, whose deletion reprograms the systemic and tumor metabolome and delays tumor growth.